- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BIIB
Recent news which mentions BIIB
7 Undervalued S&P 500 Stocks to Buy in June
June 15, 2023
From InvestorPlace
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed
June 14, 2023
From Benzinga
Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday
June 13, 2023
From Benzinga
From Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
June 13, 2023
From Benzinga
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
June 12, 2023
From Benzinga
Why Are Cruise Stocks CCL, RCL, NCLH Up Today?
June 12, 2023
From InvestorPlace
From InvestorPlace
From Benzinga
Goldman pushes back against bearish Morgan Stanley’s Mike Wilson with new 4,500 S&P 500 target
June 12, 2023
From MarketWatch
Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move
June 12, 2023
From MarketWatch
From MarketWatch
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
June 08, 2023
From Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
June 08, 2023
From Benzinga
Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio
June 07, 2023
From Benzinga
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
June 05, 2023
From Benzinga
From MarketWatch
From MarketWatch
New Alzheimer’s drug could bring hope to patients, but could be out of reach for people on Medicare
May 25, 2023
Tickers
BIIB
From MarketWatch
From InvestorPlace
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
May 19, 2023
From Motley Fool
From Motley Fool
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.